In addition to GLP-1, these include GIP, peptide YY, and cholecystokinin (CCK), among others
Choi_ Nikolai stock.adobe.com News Weight loss and diabetes medication GLP-1 agonists may interfere with cancer imaging, new study finds The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET/CT scans, new research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed. GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the United States between 2019 and 2023
To view a copy of this licence, visit About this article Cite this article Liu, Y., Hu, Y., Ma, B
When the analytes have strong albumin affinity, to substantially improve the recovery rate, it is necessary to separate the analyte-albumin complex before SPE treatment
Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer
A.CosP.DelputteP.MaesL